Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01459250 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects
A Phase 1 study of Renal Impairment, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT01459250: Completed Phase 1 study of Renal Impairment, sponsored by Novartis Pharmaceuticals.
NCT01459250 is a Phase 1 study of Renal Impairment that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 32 participants, roughly in line with the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target. The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01459250, a Phase 1 study of Renal Impairment, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will assess the pharmacokinetics, safety and tolerability of a single dose of AGO178C in subjects with mild, moderate, severe renal impairment and end-stage renal disease with that in healthy matched control subjects.
Conditions Studied
Interventions
- DRUG AGO178C
Study Locations (4)
Florida
- Novartis Investigative Site - Miami
- Novartis Investigative Site - Orlando
Minnesota
- Novartis Investigative Site - Minneapolis
Tennessee
- Novartis Investigative Site - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-03 |
| Phase | Phase 1 |
What the finished NCT01459250 record still lists
NCT01459250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, roughly in line with the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target.
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which AGO178C is the first listed.
NCT01459250 reports a single indexed study location in Florida, Minnesota, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01459250 about?
NCT01459250 is a clinical study titled "Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects". This study will assess the pharmacokinetics, safety and tolerability of a single dose of AGO178C in subjects with mild, moderate, severe renal impairment and end-stage renal disease with that in healthy matched control subjects.
What is the current status of trial NCT01459250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-03.
What conditions does trial NCT01459250 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT01459250?
The interventions under investigation include: AGO178C (DRUG).
Who is sponsoring clinical trial NCT01459250?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01459250 being conducted?
This trial has 4 study locations across Florida, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01459250's enrollment target sits among peer trials
32 12th of 32 higher than 18 of 32 other Renal Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia